HYDERABAD, INDIA (OCT 07, 2014) – Suven Life sciences Ltd (Suven) announces today that Suven is selected as one of the “Best Under A Billion” companies by Forbes Asia 2014. Forbes Asia’s “Best Under A Billion” list highlights 200 of the best small and midsized listed companies in Asia Pacific with annual revenue under $1 billion. To qualify for the selection, companies must have revenue between $5 million and $1 billion, positive net income and be publicly traded for at least a year. From a universe of 17,000 companies, qualified candidates are screened on sales growth, earnings growth and return on equity. The result is a final list featuring 200 exceptional small and midsized companies from Asia Pacific.
In recognition of the achievement of these 200 “Best Under A Billion” Companies, Forbes Asia is organizing an Award Ceremony and Dinner and Suven will receive this award on 9th December 2014 in Bangkok, Thailand.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, major depressive disorder (MDD), Huntington’s disease, Parkinson’s disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer’s disease and Schizophrenia. For more information please visit our Web site at http://www.suven.com
Help employers find you! Check out all the jobs and post your resume.
